| Breast Cancer |
1 |
1 |
| Biologic Therapy |
0 |
0.99 |
| Advanced and Metastatic Breast Cancer |
0 |
0.69 |
| Patient Safety |
0 |
0.66 |
| Nausea |
0 |
0.55 |
| Antineoplastic Drug |
0 |
0.53 |
| Adverse Effects |
0 |
0.46 |
| Breast |
0 |
0.36 |
| Cancer |
0 |
0.36 |
| Toxicology |
0 |
0.36 |
| Humanized Monoclonal Antibody |
0 |
0.27 |
| Neutropenia |
0 |
0.22 |
| Interstitial Lung Disease |
0 |
0.19 |
| Antiemetic |
0 |
0.18 |
| Clinical Guidelines |
0 |
0.18 |
| Hospital |
0 |
0.18 |
| Lung |
0 |
0.18 |
| Prophylaxis |
0 |
0.18 |
| Hodgkin Lymphoma |
0 |
0.11 |
| Hypogonadism |
0 |
0.11 |
| Antibody Drug Conjugates |
0 |
0.09 |
| California |
0 |
0.09 |
| Europe |
0 |
0.09 |
| Low Testosterone |
0 |
0.09 |
| Medical Oncology |
0 |
0.09 |